TrialClinical cancer research : an official journal of the American Association for Cancer Research2012

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

John M Kirkwood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.